E-viri
Recenzirano
Odprti dostop
-
Radin, Massimo; Sciascia, Savino; Erkan, Doruk; Pengo, Vittorio; Tektonidou, Maria G.; Ugarte, Amaia; Meroni, Pierluigi; Ji, Lanlan; Belmont, H. Michael; Cohen, Hannah; Ramires de Jesús, Guilherme; Branch, D. Ware; Fortin, Paul R.; Andreoli, Laura; Petri, Michelle; Rodriguez, Esther; Rodriguez-Pinto, Ignasi; Knight, Jason S.; Atsumi, Tatsuya; Willis, Rohan; Gonzalez, Emilio; Lopez-Pedrera, Rosario; Rossi Gandara, Ana Paula; Borges Gualhardo Vendramini, Margarete; Banzato, Alessandra; Sevim, Ecem; Barbhaiya, Medha; Efthymiou, Maria; Mackie, Ian; Bertolaccini, Maria Laura; Andrade, Danieli
Seminars in arthritis and rheumatism, December 2019, 2019-12-00, 20191201, Letnik: 49, Številka: 3Journal Article
To assess whether patients with antiphospholipid syndrome (APS) and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) when compared to patients without recurrent thrombosis. In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous) compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.